Bristol-Myers Squibb Company announced the results of ONO-4538-12 demonstrating Opdivo (nivolumab) significantly reduced the risk of death by 37% (HR 0.63; p<0.0001) in patients with previously treated advanced gastric cancer refractory to or intolerant of standard therapy, a condition without current standard-of-care treatments.
Adding hormonal therapy to radiation treatment can significantly improve the average long-term survival of men with prostate cancer who have had their prostate gland removed, according to a new Cedars-Sinai study published in the Feb. 2 issue of the New England Journal of Medicine.
Investigators from Memorial Sloan Kettering Cancer Center and Epic Sciences published findings in European Urology that only nuclear localization of AR-V7 protein in circulating tumor cells from metastatic castration-resistant prostate cancer patient blood samples is predictive of therapeutic benefit.
In an early-phase clinical trial of a new oral drug, selumetinib, children with the common genetic disorder neurofibromatosis type 1 (NF1) and plexiform neurofibromas, tumors of the peripheral nerves, tolerated selumetinib and, in most cases, responded to it with tumor shrinkage. NF1 affects one in 3,000 people.
The NCI Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
A study found a link between African ancestry and poor survival rates in patients with head and neck squamous cell carcinoma.
Genentech said FDA accepted the company's supplemental Biologics License Application and granted Priority Review for Tecentriq (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin chemotherapy, and are either previously untreated or have disease progression at least 12 months after receiving chemotherapy before surgery or after surgery.
Oncoceutics announced that it will expand the ongoing study with ONC201 in recurrent glioblastoma at Massachusetts General Hospital and Dana Farber Cancer Institute with an NCI grant awarded to Oncoceutics.
NewVac LLC reported meeting all primary endpoints in the phase II Clinical Trial of Quisinostat, novel selective oral histone deacetylase inhibitor, which NewVac licensed from Janssen Pharmaceutica NV.
Cota, a data and technology platform for value-based precision medicine, released a lung cancer study conducted jointly with Novartis that compares real-world practice patterns of genetic testing of EGFR/ALK mutations versus published guidelines.
